$50 Million

Exagen, Inc.

Initial Public Offering

Lead Left Bookrunner, September 2019

Exagen, Inc.
Exagen, Inc. is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under the AVISE® brand, several of which are based on proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. The Company’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE, and rheumatoid arthritis, or RA.